Everolimus is a semi-synthetic derivative of rapamycin that acts as a potent inhibitor of the mechanistic target of rapamycin (mTOR) complex 1. It is primarily used clinically for its immunosuppressant and anti-proliferative properties, though it is increasingly studied for its potential to modulate biological aging and enhance healthspan.

Overview

Everolimus (trade names Afinitor, Zortress, Certican) is a 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus) developed by Novartis to improve the oral bioavailability and pharmacokinetic profile of the parent macrolide. Like sirolimus, everolimus forms a complex with the intracellular immunophilin FKBP12, and this complex allosterically inhibits the mechanistic target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that serves as a master regulator of cell growth, proliferation, metabolism, and autophagy.

By inhibiting mTORC1, everolimus suppresses phosphorylation of key downstream effectors including S6 kinase 1 (S6K1) and 4E-BP1, resulting in reduced protein synthesis, cell cycle arrest (primarily in G1 phase), and induction of autophagy. In oncology, everolimus is FDA-approved for advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin, hormone receptor-positive HER2-negative breast cancer (in combination with exemestane), tuberous sclerosis complex-associated renal angiomyolipomas and subependymal giant cell astrocytomas, and certain forms of transplant rejection prophylaxis. Its anti-angiogenic effects, mediated through reduced VEGF production downstream of mTORC1, contribute to its antitumor activity.

The intersection of mTOR inhibition and aging biology has generated substantial interest in everolimus as a potential geroprotective agent. A landmark 2014 study by Mannick et al. demonstrated that low-dose everolimus enhanced immune function in elderly subjects by approximately 20% improvement in influenza vaccine response. Subsequent research has explored mTOR inhibition for age-related decline in immune function (immunosenescence), neurodegeneration, and cardiovascular aging. The key challenge remains achieving the anti-aging benefits of partial mTORC1 inhibition while avoiding the immunosuppressive and metabolic side effects (hyperglycemia, dyslipidemia, stomatitis) associated with higher doses used in oncology and transplantation.

Mechanism of Action

mTORC1 Inhibition

Everolimus is a 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus) that functions as an allosteric inhibitor of mechanistic target of rapamycin complex 1 (mTORC1). It binds the intracellular immunophilin FKBP12 (FK506-binding protein 12), forming a binary complex that associates with the FRB domain of mTOR, preventing mTORC1 from phosphorylating its key substrates p70S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) (PMID: 19461509).

Downstream Translational Control

Inhibition of S6K1 reduces phosphorylation of ribosomal protein S6, decreasing translation of mRNAs containing 5' terminal oligopyrimidine (5'TOP) tracts — these encode ribosomal proteins and elongation factors essential for protein synthesis capacity. Simultaneously, hypophosphorylated 4E-BP1 sequesters eIF4E, blocking cap-dependent translation initiation of oncogenic mRNAs including cyclin D1, c-Myc, HIF-1alpha, and VEGF (PMID: 22203767).

Cell Cycle Arrest & Autophagy

By suppressing mTORC1 signaling, everolimus induces G1 cell cycle arrest through downregulation of cyclin D1 and upregulation of p27Kip1. It simultaneously activates autophagy via de-repression of the ULK1/ATG13/FIP200 complex, which mTORC1 normally phosphorylates to suppress autophagosome formation. This dual mechanism — proliferative arrest plus enhanced autophagy — underpins both its antitumor and immunosuppressive activities (PMID: 25484100).

Anti-Angiogenic & Immunosuppressive Effects

Everolimus reduces VEGF secretion from tumor cells by suppressing HIF-1alpha translation, impairing tumor angiogenesis. In T lymphocytes, it blocks IL-2-driven proliferation by preventing mTORC1-mediated metabolic reprogramming from oxidative phosphorylation to glycolysis, a switch required for clonal expansion. This selective immunosuppression underlies its use in transplant medicine (PMID: 24803579).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Everolimus (FDA Approved)

Overview Everolimus (brand names Afinitor, Zortress, Certican) is an FDA-approved mTOR (mechanistic target of rapamycin) inhibitor used for multiple indications including advanced renal cell carcinoma, breast cancer, neuroendocrine tumors, tuberous sclerosis complex, and organ transplant rejection prophylaxis. It is a potent immunosuppressive and antiproliferative agent with a significant side effect profile requiring close medical monitoring.

Common Side Effects

• Stomatitis/oral mucositis (44-78%): the most frequent adverse effect, often dose-limiting; managed with dexamethasone mouthwash
• Infections (20-50%): including upper respiratory infections, urinary tract infections, and pneumonia due to immunosuppression
• Rash and skin toxicity (25-59%): acneiform rash, pruritus, dry skin
• Fatigue and asthenia (20-45%)
• Diarrhea (19-34%), nausea (16-29%), and decreased appetite
• Peripheral edema (20-45%)
• Hyperglycemia (12-57%) and hyperlipidemia (hypercholesterolemia 30-77%, hypertriglyceridemia 27-73%)

Serious Adverse Effects

• Non-infectious pneumonitis (12-19%): potentially fatal interstitial lung disease; monitor for new or worsening respiratory symptoms; may require dose reduction or discontinuation
• Severe immunosuppression: increased risk of opportunistic infections including Pneumocystis jirovecii, BK virus, CMV, and invasive fungal infections
• Hepatotoxicity: elevated transaminases, hepatic failure reported rarely
• Renal toxicity: proteinuria, increased serum creatinine; particularly when combined with calcineurin inhibitors
• Thrombotic microangiopathy/hemolytic uremic syndrome: reported in transplant patients
• Impaired wound healing: significant concern post-surgery
• Myelosuppression: anemia (45-92%), lymphopenia, thrombocytopenia, neutropenia
• Angioedema: particularly when co-administered with ACE inhibitors

Contraindications

• Known hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives
• Severe hepatic impairment (Child-Pugh C) for oncology indications
• Severe uncontrolled infection
• Live vaccine administration during treatment
• Pregnancy (Category D): causes fetal harm; effective contraception required during and for 8 weeks after treatment

Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): dramatically increase everolimus levels — contraindicated or require significant dose reduction
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort): substantially reduce everolimus levels, potentially rendering treatment ineffective
• Calcineurin inhibitors (cyclosporine, tacrolimus): complex interaction in transplant settings; cyclosporine increases everolimus levels
• ACE inhibitors: increased angioedema risk
• Live vaccines: contraindicated due to immunosuppression; inactivated vaccines may have reduced efficacy
• Grapefruit and grapefruit juice: CYP3A4 inhibition increases everolimus exposure

Special Populations

• Hepatic impairment: dose reduction required for mild (Child-Pugh A) and moderate (Child-Pugh B) impairment
• Renal impairment: no dose adjustment needed but monitor closely
• Elderly: no specific dose adjustment; increased susceptibility to side effects
• Fertility: may cause male and female infertility; spermatogenesis may be affected

Dosage Considerations

• Oncology: 10 mg once daily (dose reductions to 5 mg or 2.5 mg for toxicity)
• Transplant: 0.75 mg twice daily initially, adjusted by therapeutic drug monitoring (target trough 3-8 ng/mL)
• Therapeutic drug monitoring is essential for transplant indications
• Take consistently with or without food at the same time daily

Pharmacokinetic Profile